# FDA 483 - Dr. Arun Ravindran, MBBS MSc., PhD - January 11, 2019

Source: https://www.globalkeysolutions.net/records/483/dr-arun-ravindran-mbbs-msc-phd/08469234-4ed9-4c30-ad74-c6300b707bc3

> FDA 483 for Dr. Arun Ravindran, MBBS MSc., PhD on January 11, 2019. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Dr. Arun Ravindran, MBBS MSc., PhD
- Inspection Date: 2019-01-11
- Product Type: drugs
- Office Name: Center for Veterinary Medicine
- Summary: The FDA inspected Dr. Arun Ravindran, a clinical investigator in Toronto, regarding a study on Esketamine for treatment-resistant depression. The inspection revealed that the investigation was not conducted in accordance with the investigational plan. Specifically, two subjects were enrolled and treated with investigational product despite meeting exclusion criteria related to prohibited concomitant therapies.

## Related Officers

- [Assistant Country Director, Regulatory Specialist BIMO](https://www.globalkeysolutions.net/people/alanna-l-mussawwir-bias/1283ff1a-34dd-4d90-9389-7bff2570527d)

Company: https://www.globalkeysolutions.net/companies/dr-arun-ravindran-mbbs-msc-phd/95c2a8ff-dcfb-4ce0-8597-ca907d8659f3

Office: https://www.globalkeysolutions.net/offices/center-for-veterinary-medicine/7e30a309-56e4-4e7a-8b8b-e07674bb07b4